OR WAIT null SECS
- About Us
- Advertise
- Editorial
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Pharma Pulse 4/3/25: Analyzing the Theranos Appeals, Current CAR-T Therapy Trends in Managed Care & more
The latest news for pharma industry insiders.
Analyzing the Theranos Appeals
Matthew Yelovich, partner at Cleary Gottlieb, discusses the appeals of Elizabeth Holmes and Ramesh "Sunny" Balwani and the Ninth Circuit's recent affirmation of their convictions.
Current CAR-T Therapy Trends in Managed Care | AMCP Annual 2025
Balancing the cost, access to and risk management of CAR-T cell therapies is critical, according to a panel of experts who presented at the annual meeting of the Academy of Managed Care Pharmacy in Houston.
Roche’s Top Drug’s New High-Dose Version Fails in Study
Roche Holding AG said a high-dose version of Ocrevus, its multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability to fend off cheaper copies.
Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025
The "Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering.
Personalized cancer vaccines are emerging as a transformative force in next generation cancer treatment methodology, with emergent commercial potential fueled by advancements in biotechnology and an increasing demand for targeted therapies. These vaccines represent a tailored approach to cancer treatment, utilizing a patient's unique genetic makeup to craft vaccines that specifically target and eliminate cancer cells. The success of this approach is gaining traction, and the market for personalized cancer vaccines is expected to grow significantly by 2030. Companies like BioNTech, Moderna, and smaller players such as myNEO Therapeutics are at the forefront, using their expertise in mRNA technology, which was initially honed during the COVID-19 pandemic.
It was a pleasure speaking with Nicholas Saraceno of Pharmaceutical Commerce about cost-shifting programs: copay accumulators, maximizers, and alternative funding programs. Check out part one of my interview below, which lays out the basics of the programs.
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
Related Content:
